Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Inventory (2017 - 2025)

Historic Inventory for Ptc Therapeutics (PTCT) over the last 9 years, with Q3 2025 value amounting to $52.7 million.

  • Ptc Therapeutics' Inventory rose 4770.54% to $52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.7 million, marking a year-over-year increase of 4770.54%. This contributed to the annual value of $23.2 million for FY2024, which is 2414.56% down from last year.
  • Ptc Therapeutics' Inventory amounted to $52.7 million in Q3 2025, which was up 4770.54% from $34.1 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Inventory registered a high of $52.7 million during Q3 2025, and its lowest value of $14.8 million during Q3 2022.
  • Over the past 5 years, Ptc Therapeutics' median Inventory value was $23.2 million (recorded in 2024), while the average stood at $25.5 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Inventory soared by 14137.19% in 2023, and later plummeted by 2788.94% in 2025.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Inventory stood at $15.9 million in 2021, then skyrocketed by 37.54% to $21.8 million in 2022, then soared by 40.21% to $30.6 million in 2023, then fell by 24.15% to $23.2 million in 2024, then skyrocketed by 127.16% to $52.7 million in 2025.
  • Its last three reported values are $52.7 million in Q3 2025, $34.1 million for Q2 2025, and $21.7 million during Q1 2025.